ANK3 seems to be the most solid candidate, being predicted by 3 out of 4 programs: in particular, it results a suitable target for miR-182, which is greatly up-regulated at 11 months in tumor samples compared to controls. The gene discussed is ANK3; the disease is neoplasm.